Journal article · 2026 · Open access

Perioperative ivonescimab with or without chemotherapy in resectable non-small cell lung cancer: a phase 2 trial

Xiaoliang Zhao, Bin Zhang, Chenguang Li, Lianmin Zhang, Meng Wang, Ziqiang Tian, Shengguang Wang, Qiang Zhang, Huilai Lv, Chong Pang, Shiwang Wen, Xiaofei Wang and 19 more

Nature Medicine · Published 4 November 2026 · DOI 10.1038/s41591-026-04745-4

Open PDFView at the publisherCite this paper

In brief

“Perioperative ivonescimab with or without chemotherapy in resectable non-small cell lung cancer: a phase 2 trial” is a 2026 journal article by Xiaoliang Zhao and 30 co-authors, published in Nature Medicine. OpenAlex counts 0 citations as of 17 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Nature Medicine.

Citations
0
References
30
Authors
31

Abstract

Resectable non-small cell lung cancer (NSCLC) carries a high risk of postoperative recurrence, underscoring the need for effective perioperative therapies. This nonrandomized, noncomparative phase 2 trial evaluated neoadjuvant ivonescimab monotherapy (cohort 1) or in combination with chemotherapy (cohort 2), followed by surgery and adjuvant ivonescimab. In cohort 2, the major pathological response (MPR) rate was 70.1% (47/67; 95% confidence interval (CI) = 57.7-80.7); the lower bound of the 80% two-sided CI exceeded the historical control rate of 41% and the primary endpoint was met. The MPR rate in cohort 1 was 60.0% (6/10; 95% CI = 26.2-87.8). Among patients who achieved MPR, 83.3% (5/6) in cohort 1 and 97.9% (46/47) in cohort 2 had residual viable tumor (RVT) of ≤5%, respectively. Grade 3 or higher treatment-related adverse events (AEs) occurred in 36.4% (4/11) patients in cohort 1 and 30.4% (24/79) of those in cohort 2, with no grade 3 or higher hemorrhage or treatment-related death. Treatment-related surgery delay occurred in one (1.3%) patient. Surgery-related AEs related to ivonescimab occurred in 10.0% (1/10) and 10.4% (7/67) patients in the two cohorts, respectively, with no grade 3 or higher events reported. These data support perioperative ivonescimab with or without chemotherapy as a promising strategy for resectable NSCLC. ClinicalTrials.gov identifier: NCT05247684 .

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Zhao, X., Zhang, B., Li, C., Zhang, L., Wang, M., Tian, Z., Wang, S., Zhang, Q., Lv, H., Pang, C., Wen, S., Wang, X., Wei, W., Zhang, Y., Wuhao, H., Zhu, J., Li, Y., Chen, C., Tang, Y., . . . Wang, C. (2026). Perioperative ivonescimab with or without chemotherapy in resectable non-small cell lung cancer: a phase 2 trial. Nature Medicine. https://doi.org/10.1038/s41591-026-04745-4

MLA 9

Zhao, Xiaoliang, et al. “Perioperative ivonescimab with or without chemotherapy in resectable non-small cell lung cancer: a phase 2 trial.” Nature Medicine, 2026. https://doi.org/10.1038/s41591-026-04745-4.

Chicago

Zhao, Xiaoliang, Bin Zhang, Chenguang Li, Lianmin Zhang, Meng Wang, Ziqiang Tian, Shengguang Wang, et al. 2026. “Perioperative ivonescimab with or without chemotherapy in resectable non-small cell lung cancer: a phase 2 trial.” Nature Medicine. https://doi.org/10.1038/s41591-026-04745-4.

Harvard

Zhao, X. et al. (2026) ‘Perioperative ivonescimab with or without chemotherapy in resectable non-small cell lung cancer: a phase 2 trial’, Nature Medicine. doi:10.1038/s41591-026-04745-4.

IEEE

X. Zhao et al., “Perioperative ivonescimab with or without chemotherapy in resectable non-small cell lung cancer: a phase 2 trial,” Nature Medicine, 2026, doi: 10.1038/s41591-026-04745-4.

BibTeX

@article{zhao2026perioperative,
  title     = {{Perioperative ivonescimab with or without chemotherapy in resectable non-small cell lung cancer: a phase 2 trial}},
  author    = {Zhao, Xiaoliang and Zhang, Bin and Li, Chenguang and Zhang, Lianmin and Wang, Meng and Tian, Ziqiang and Wang, Shengguang and Zhang, Qiang and Lv, Huilai and Pang, Chong and Wen, Shiwang and Wang, Xiaofei and Wei, Wei and Zhang, Yu and Wuhao, Huang and Zhu, Jianquan and Li, Yue and Chen, Chen and Tang, Yao and Jia, Bin and Zhang, Hua and Chen, Hui and Wang, Sha and Zhang, Jun-Ye and Li, Wenting and Wang, Zhongmin Maxwell and Li, Boning and Xia, Michelle and Zhang, Zhenfa and Yue, Dongsheng and others},
  journal   = {Nature Medicine},
  year      = {2026},
  doi       = {10.1038/s41591-026-04745-4},
  url       = {https://doi.org/10.1038/s41591-026-04745-4}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment

  • ivonescimab
  • resectable non-small cell lung cancer
  • perioperative therapy
  • neoadjuvant therapy
  • adjuvant therapy
  • combination chemotherapy
  • major pathological response
  • residual viable tumor

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Zhao, X., Zhang, B., Li, C., Zhang, L., Wang, M., Tian, Z., Wang, S., Zhang, Q., Lv, H., Pang, C., Wen, S., Wang, X., Wei, W., Zhang, Y., Wuhao, H., Zhu, J., Li, Y., Chen, C., Tang, Y., . . . Wang, C. (2026). Perioperative ivonescimab with or without chemotherapy in resectable non-small cell lung cancer: a phase 2 trial. Nature Medicine. https://doi.org/10.1038/s41591-026-04745-4

How many times has this paper been cited?

0 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Nature Medicine: sign in and open the PDF from this page.

Who wrote this paper?

Xiaoliang Zhao, Bin Zhang, Chenguang Li, Lianmin Zhang, Meng Wang, Ziqiang Tian, Shengguang Wang, Qiang Zhang, Huilai Lv, Chong Pang, Shiwang Wen, Xiaofei Wang and 19 more.

What is the DOI of this paper?

10.1038/s41591-026-04745-4, permanently at https://doi.org/10.1038/s41591-026-04745-4. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.